Skip to main content
Premium Trial:

Request an Annual Quote

IntegraGen Theranostic Test for Colorectal Cancer Gets CE-IVD Mark

NEW YORK (GenomeWeb) – IntegraGen today announced that its test kit for predicting patient response to anti-EGFR therapy has been CE-IVD marked, and the company will launch it in the European Union.

The test, miRpredX 31-3p, is a positive theranostic test for patients with metastatic colorectal cancer that quantifies the expression of miR-31-3p in formalin-fixed, paraffin-embedded tumor samples using standard quantitative reverse-transcription PCR, IntegraGen said. It added that miRpredX 31-3p predicts the potential clinical benefits associated with first-line anti-EGFR therapy compared to anti-VEGF therapy, or when second or additional lines of treatment with an anti-EGFR therapy is beneficial, compared to chemotherapy by itself, for patients with RAS wild-type mCRC.

A recent study demonstrated the utility of miR-31-3p expression as a predictive marker for overall survival and response to anti-EGFR therapy treatment, Évry, France-based IntegraGen said.

Achieving CE-IVD marking follows five years of development work and clinical validation of the test, IntegraGen Director of Molecular Diagnostics Yann Gaston-Mathé said in a statement. He added that the worldwide market for miR-31-3p testing is estimated to be $150 million. 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more